Vtama cream approved for treatment of psoriasis, atopic dermatitis in Japan

Key takeaways:

• Dermavant Sciences partner, Japan Tobacco, received approval for Vtama cream 1% in Japan.
• Approved indications include adults with psoriasis and patients aged 12 years and older with atopic dermatitis.

Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press release.

In 2020, Dermavant and Japan Tobacco entered a licensing agreement whereby Japan Tobacco received the exclusive rights to develop, register and market Vtama (tapinarof) cream 1% in Japan.

“I believe Japan Tobacco’s approval speaks to tapinarof’s unique proposition in Japan as a once-daily, cosmetically elegant and steroid-free, topical cream for both acute treatment and long-term management of psoriasis and atopic dermatitis and we applaud our partner’s success,” Todd Zavodnick, CEO of Dermavant, said in the release.

In the U.S., Vtama cream 1% is currently approved for the topical treatment of plaque psoriasis in adults. As Healio previously reported in April 2024, the FDA accepted Dermavant’s supplemental new drug application to expand Vtama’s indication to atopic dermatitis in adults and children aged 2 years and older. The application’s Prescription Drug User Fee Act action date is set for quarter four of this year.

“Our commitment to bringing Vtama cream 1% to as many U.S. patients as we can remains resolute,” Zavodnick said.